Treatment and outcome of Hodgkin lymphoma (HL) are the true success story of modern medicine. The data from the developing countries on long-term outcome of patients with HL is sparse.
Primary objective is to assess the progression-free survival (PFS). Secondary objective are overall survival (OS) and toxicities.
SETTINGS AND DESIGN